We are studying the effects of ELA026 on survival in patients with sHLH triggered by lymphoma. This trial will help us understand how well this treatment works and its safety.
Health conditions and diseases that the clinical trial is designed to study and treat.
Secondary Hemophagocytic Lymphohistiocytosis (sHLH) is a rare but serious condition where the immune system becomes overly activated, leading to excessive inflammation and damage to organs. It often occurs as a response to infections, autoimmune diseases, or certain cancers.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
